| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/14/2007 | EP1628662B1 Benzothiazole derivatives and use thereof in the treatment of diseases related to the adenosine a2a receptor |
| 02/14/2007 | EP1615644B1 Substituted 4-phenyl-4-[1h-imidazol-2-yl]-piperidine derivatives and their use as selective non-peptide delta opioid agonists with antidepressant and anxiolytic activity |
| 02/14/2007 | EP1583523B1 Use of hydroxamic acid derivatives for the preparation of anti-tumour medicaments |
| 02/14/2007 | EP1575563B1 Non-hygroscopic formulation comprising a hydroscopic drug |
| 02/14/2007 | EP1562944B1 Pyrazoloquinolines with immunomodulating activity |
| 02/14/2007 | EP1560828B9 Imidazoquinoline derivatives as adenosine a3 receptor ligands |
| 02/14/2007 | EP1551835B1 Novel 1,4-diazabicycloalkane derivatives, their preparation and use |
| 02/14/2007 | EP1539796B1 Anti-inflammatory or anti-allergic androstane complexes |
| 02/14/2007 | EP1536777B1 Use of nf-kappa b inhibitors for the treatment of mastitis |
| 02/14/2007 | EP1534391B1 Novel piperazinyl-pyrazinone derivatives for the treatment of 5-ht2a receptor-related disorders |
| 02/14/2007 | EP1533292B1 Dibenzylamine compound and medicinal use thereof |
| 02/14/2007 | EP1532121B1 New use of pyrimidine - or triazine- 2-carbonitiles for treating diseases associated with cysteine protease activity and novel pyrimidine-2-carbonitile derivatives |
| 02/14/2007 | EP1523485B1 3-furanyl analogs of toxoflavine as kinase inhibitors |
| 02/14/2007 | EP1515963B1 A process for preparation of optically pure or optically enriched sulfoxide compounds, including amorphous esomeprazole and salts thereof |
| 02/14/2007 | EP1507514B1 Controlled release compositions of estradiol metabolites |
| 02/14/2007 | EP1505956B1 A method to improve surface properties of pharmaceutical tablets |
| 02/14/2007 | EP1496909B1 Combination therapy for the treatment of cancer |
| 02/14/2007 | EP1494629B1 Condom |
| 02/14/2007 | EP1490392B1 Steroidal quinols as prodrugs of antioxidants |
| 02/14/2007 | EP1485059B1 Topical dapsone for the treatment of acne |
| 02/14/2007 | EP1444220B1 Compounds and method for the treatment of overactive bladder |
| 02/14/2007 | EP1438045B1 Use of indole and indoline derivatives in the treatment of obesity or for the reduction of food intake |
| 02/14/2007 | EP1435943B1 Use of 2-oxo-1-pyrrolidine derivatives for the preparation of a drug for treating dyskinesia |
| 02/14/2007 | EP1414409B1 Stabilized oral suspension formulation |
| 02/14/2007 | EP1402886B1 Lipolysis accelerator for reducing body weight and medicinal use |
| 02/14/2007 | EP1395586B1 Method for the production of zolpidem |
| 02/14/2007 | EP1395554B1 Substituted carbazoles as inhibitors of spla2 |
| 02/14/2007 | EP1392355B1 Use of proteasome inhibitors to treat dry eye disorders |
| 02/14/2007 | EP1370552B1 Rho-kinase inhibitors |
| 02/14/2007 | EP1368349B1 Xanthine derivative, production and use thereof as a medicament |
| 02/14/2007 | EP1368336B9 Thiophene substituted amine derivatives as glyt-1 inhibitors |
| 02/14/2007 | EP1345928B1 Pyrazole compounds useful as protein kinase inhibitors |
| 02/14/2007 | EP1343757B1 Indole derivatives |
| 02/14/2007 | EP1341790B1 Sulfonamido ether substituted imidazoquinolines |
| 02/14/2007 | EP1339701B1 Heteroaryl alkyl piperazine derivatives as fatty acid oxidation inhibitors |
| 02/14/2007 | EP1328277B1 Bisphosphonic compounds for strengthening of cortical bone |
| 02/14/2007 | EP1299378B1 Tetrahydropyridino or piperidino heterocyclic derivatives |
| 02/14/2007 | EP1296961B1 1,4-diazepan-2,5-dione derivatives and their use as nk-1 receptor antagonists |
| 02/14/2007 | EP1294715B1 Quinazoline ditosylate salt compounds |
| 02/14/2007 | EP1280515B1 Pharmaceutical compositions comprising cannabis |
| 02/14/2007 | EP1278763B1 3-nitrogen-6,7-dioxygen steroids and uses related thereto |
| 02/14/2007 | EP1272531B8 Crystalline mixtures of partial methyl ethers of beta-cyclodextrin and related compounds |
| 02/14/2007 | EP1267857B1 In vitro use of astaxanthin for pretreatment of cells prior to UV-exposure to inhibit the activation of NF-kB |
| 02/14/2007 | EP1259234B9 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy |
| 02/14/2007 | EP1225892B1 Use of hypoestoxides as antiparasitic agents |
| 02/14/2007 | EP1171144B1 Use of tetrahydrocurcuminoids to regulate physiological and pathological events in the skin and mucosa |
| 02/14/2007 | EP1143976B9 Beta-d-2', 3' -didehydro-2', 3' -dideoxy-5-fluorocytidine for use in the treatment of hiv infections |
| 02/14/2007 | EP1140147B1 hCG THERAPY FOR THE TREATMENT OF METASTATIC BREAST CANCER |
| 02/14/2007 | EP1128813B1 An inhalation system |
| 02/14/2007 | EP1126836B1 Benzamide potassium channel inhibitors |
| 02/14/2007 | EP1083929B1 The use of anabolic agents, anti-catabolic agents, antioxidant agents, and analgesics for protection, treatment and repair of connective tissues in humans and animals |
| 02/14/2007 | EP1066030B1 Topical hormonal composition with systemic effect |
| 02/14/2007 | EP1063982B1 Antagonists for treatment of cd11/cd18 adhesion receptor mediated disorders |
| 02/14/2007 | EP1017676B1 Method for the synthesis of quinoline derivatives |
| 02/14/2007 | EP1009413B1 Use of immunostimulatory oligonucleotides for preventing or treating asthma |
| 02/14/2007 | EP0999845B1 Treatment of diabetes with thiazolidinedione and sulphonylurea |
| 02/14/2007 | EP0871713B1 The use of lecithin-cholesterol acyltransferase (lcat) in the treatment of atherosclerosis |
| 02/14/2007 | EP0820283B1 Lactacystin analogs |
| 02/14/2007 | EP0788346B9 Emulsified drug delivery systems |
| 02/14/2007 | EP0707476B1 Compounds for the photodecontamination of pathogens in blood |
| 02/14/2007 | EP0662077B1 Cd27 ligand |
| 02/14/2007 | CN1914335A Antisense oligonucleotide modulation of STAT3 expression |
| 02/14/2007 | CN1914225A HCV NS-3 serine protease inhibitors |
| 02/14/2007 | CN1914224A HCV NS-3 serine protease inhibitors |
| 02/14/2007 | CN1914220A Prodrug comprising 5-aminosalicylate glycoside |
| 02/14/2007 | CN1914215A Vanadium compounds as inhibitors of phosphatases |
| 02/14/2007 | CN1914214A Tricycle indole hydroxyethlamine derivatives and their use in the treatment of alzheimer's disease |
| 02/14/2007 | CN1914212A Polymorphic forms of a GABAA agonist |
| 02/14/2007 | CN1914211A Preventive or therapeutic agent for diabetic maculopathy |
| 02/14/2007 | CN1914209A Diaza- or thiazadione derivatives with neuroprotective activity |
| 02/14/2007 | CN1914208A Substituted 8'-pyri(mi)dinyl-dihydrospiro-[cycloalklymine]-pyrimido[1,2a]pyrimidin-6-one derivatives |
| 02/14/2007 | CN1914207A Azepinoindole derivatives as pharmaceutical agents |
| 02/14/2007 | CN1914206A 7-phenylamino-4-quinolone-3-carboxylic acid derivatives, methods for production and use thereof as medicaments |
| 02/14/2007 | CN1914205A Pyrazolo[3,4-b] pyridine compounds, and their use as phosphodiesterase inhibitors |
| 02/14/2007 | CN1914204A Naphthyridine derivatives and their use as modulators of muscarinic receptors |
| 02/14/2007 | CN1914201A 烟碱乙酰胆碱受体配体 Nicotinic acetylcholine receptor ligands |
| 02/14/2007 | CN1914200A Nicotinic acetylcholine receptor ligands |
| 02/14/2007 | CN1914199A Pyridinyl - or pyrimidinyl thiazoles with protein kinase inhibiting activity |
| 02/14/2007 | CN1914196A 5- or 6-substituted benzimidazole derivatives as inhibitors of respiratiory syncytial virus replication |
| 02/14/2007 | CN1914195A Substituted quinoline compounds |
| 02/14/2007 | CN1914194A Therapeutic agent for vasospasm accompanying bypass operation |
| 02/14/2007 | CN1914193A Heterocyclic anti-migraine agents |
| 02/14/2007 | CN1914191A Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide |
| 02/14/2007 | CN1914189A Spiro-benzodioxoles and their use as CB1 antagonists |
| 02/14/2007 | CN1914188A Cationic substituted benzofurans as antimicrobial agents |
| 02/14/2007 | CN1914187A Crystalline polymorphs of a CXC-chemokine receptor ligand |
| 02/14/2007 | CN1914184A Urea derivatives |
| 02/14/2007 | CN1914182A 喹唑啉衍生物 Quinazoline derivatives |
| 02/14/2007 | CN1914180A Indazole derivatives as inhibitors of hormone-sensitive lipases |
| 02/14/2007 | CN1914179A Immobilized n-substituted tricyclic 3-aminopyrazoles for the identification of biomolecular targets |
| 02/14/2007 | CN1914176A Process for preparing aripiprazole |
| 02/14/2007 | CN1914175A Method of making 7-(4-bromobutoxy)-3,4-dihydrocarbostyril |
| 02/14/2007 | CN1914174A Methods of preparing aripiprazole crystalline forms |
| 02/14/2007 | CN1914171A Hydroisoindoline tachykinin receptor antagonists |
| 02/14/2007 | CN1914169A Nitric oxide releasing prodrugs of diaryl-2-(5h)-furanones as cyclooxygenase-2 inhibitors |
| 02/14/2007 | CN1914168A Peptidyl arginine deiminase type IV inhibitor |
| 02/14/2007 | CN1914153A Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides and use as renin inhibitors |
| 02/14/2007 | CN1914152A New compounds, methods for their preparation and use thereof |
| 02/14/2007 | CN1914151A Nitric oxide releasing prodrugs of diaryl-2-(5h)-furanones as cyclooxygenase-2 inhibitors |
| 02/14/2007 | CN1914149A Combination therapy for treating cyclooxygenase-2 mediated diseases or conditions in patients at risk of thrombotic cardiovascular events |